These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 28298630)

  • 1. Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics.
    Li QQ; Hao JJ; Zhang Z; Krane LS; Hammerich KH; Sanford T; Trepel JB; Neckers L; Agarwal PK
    Sci Rep; 2017 Mar; 7(1):201. PubMed ID: 28298630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: A proteomic approach.
    Li QQ; Hao JJ; Zhang Z; Hsu I; Liu Y; Tao Z; Lewi K; Metwalli AR; Agarwal PK
    Int J Oncol; 2016 Jun; 48(6):2591-607. PubMed ID: 27082124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hsp90 inhibition by AUY922 as an effective treatment strategy against myxoid liposarcoma.
    Steinmann S; Gali-Muhtasib H; Huebner K; Al-Halabi R; Abou Merhi R; Aman P; Agaimy A; Haller F; Schneider-Stock R
    Cancer Lett; 2015 Oct; 367(2):147-56. PubMed ID: 26225840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.
    Jensen MR; Schoepfer J; Radimerski T; Massey A; Guy CT; Brueggen J; Quadt C; Buckler A; Cozens R; Drysdale MJ; Garcia-Echeverria C; Chène P
    Breast Cancer Res; 2008; 10(2):R33. PubMed ID: 18430202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E253-61. PubMed ID: 25389633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.
    Acquaviva J; He S; Zhang C; Jimenez JP; Nagai M; Sang J; Sequeira M; Smith DL; Ogawa LS; Inoue T; Tatsuta N; Knowles MA; Bates RC; Proia DA
    Mol Cancer Res; 2014 Jul; 12(7):1042-54. PubMed ID: 24784839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the novel HSP90 inhibitor AUY922 in hepatocellular carcinoma: Potential for therapy.
    Cheng W; Ainiwaer A; Xiao L; Cao Q; Wu G; Yang Y; Mao R; Bao Y
    Mol Med Rep; 2015 Aug; 12(2):2451-6. PubMed ID: 25955495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heat Shock Protein 90 Inhibitor Effects on Pancreatic Cancer Cell Cultures.
    Gulla A; Kazlauskas E; Liang H; Strupas K; Petrauskas V; Matulis D; Eshleman JR
    Pancreas; 2021 Apr; 50(4):625-632. PubMed ID: 33939678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake.
    Monazzam A; Razifar P; Ide S; Rugaard Jensen M; Josephsson R; Blomqvist C; Langström B; Bergström M
    Nucl Med Biol; 2009 Apr; 36(3):335-42. PubMed ID: 19324279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation.
    Chan KC; Ting CM; Chan PS; Lo MC; Lo KW; Curry JE; Smyth T; Lee AW; Ng WT; Tsao GS; Wong RN; Lung ML; Mak NK
    Mol Cancer; 2013 Oct; 12(1):128. PubMed ID: 24156782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heat shock protein 90 inhibitors induce functional inhibition of human natural killer cells in a dose-dependent manner.
    Huyan T; Li Q; Dong DD; Yang H; Zhang J; Huang QS; Yin DC; Shang P
    Immunopharmacol Immunotoxicol; 2016; 38(2):77-86. PubMed ID: 26642940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiosensitization of HSF-1 Knockdown Lung Cancer Cells by Low Concentrations of Hsp90 Inhibitor NVP-AUY922.
    Kühnel A; Schilling D; Combs SE; Haller B; Schwab M; Multhoff G
    Cells; 2019 Sep; 8(10):. PubMed ID: 31569342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer.
    Jansson KH; Tucker JB; Stahl LE; Simmons JK; Fuller C; Beshiri ML; Agarwal S; Fang L; Hynes PG; Alilin AN; Lake R; Abbey YC; Cawley J; Tice CM; Yin J; McKnight C; Klummp-Thomas C; Zhang X; Guha R; Hoover S; Simpson RM; Nguyen HM; Corey E; Thomas CJ; Proia DA; Kelly K
    Sci Rep; 2018 Nov; 8(1):17239. PubMed ID: 30467317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.
    Kaiser M; Lamottke B; Mieth M; Jensen MR; Quadt C; Garcia-Echeverria C; Atadja P; Heider U; von Metzler I; Türkmen S; Sezer O
    Eur J Haematol; 2010 Apr; 84(4):337-44. PubMed ID: 20028416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
    Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK
    Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor Explants.
    Nguyen EV; Centenera MM; Moldovan M; Das R; Irani S; Vincent AD; Chan H; Horvath LG; Lynn DJ; Daly RJ; Butler LM
    Mol Cell Proteomics; 2018 Aug; 17(8):1470-1486. PubMed ID: 29632047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heat shock protein 90 inhibitor NVP-AUY922 exerts potent activity against adult T-cell leukemia-lymphoma cells.
    Taniguchi H; Hasegawa H; Sasaki D; Ando K; Sawayama Y; Imanishi D; Taguchi J; Imaizumi Y; Hata T; Tsukasaki K; Uno N; Morinaga Y; Yanagihara K; Miyazaki Y
    Cancer Sci; 2014 Dec; 105(12):1601-8. PubMed ID: 25263741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
    Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
    Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.
    Rouhi A; Miller C; Grasedieck S; Reinhart S; Stolze B; Döhner H; Kuchenbauer F; Bullinger L; Fröhling S; Scholl C
    Oncotarget; 2017 Jan; 8(5):7678-7690. PubMed ID: 28032595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heat shock protein 90 (HSP90) is overexpressed in p16-negative oropharyngeal squamous cell carcinoma, and its inhibition in vitro potentiates the effects of chemoradiation.
    Patel K; Wen J; Magliocca K; Muller S; Liu Y; Chen ZG; Saba N; Diaz R
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1015-22. PubMed ID: 25205430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.